This HTML5 document contains 57 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
n8http://dx.doi.org/10.1210/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q73892792
rdf:type
wikibase:Item
schema:description
наукова стаття, опублікована в червні 2000 գիտական հոդված հրատարակված 2000 թվականի հունիսի 1-ին scientific article published on 01 June 2000 im Juni 2000 veröffentlichter wissenschaftlicher Artikel artículu científicu espublizáu en xunu de 2000 wetenschappelijk artikel
p:P577
wds:Q73892792-05A11B55-A48F-4B6E-B51C-1EA3016AD331
wdt:P577
2000-06-01T00:00:00Z
p:P407
wds:Q73892792-FB7085D4-FC02-4D96-BAC1-4A8C07CB77A9
wdt:P407
wd:Q1860
p:P2093
wds:Q73892792-5CFBB9B1-C9C1-4542-A501-D276F7CD11CE wds:Q73892792-3D7AEC88-47D0-4C95-81C9-1AE5C5810FA2 wds:Q73892792-CCDC029C-89F0-4460-A76B-116062684F18 wds:Q73892792-9E7EFA57-EAD0-4C65-A91A-2AFEF808A2E6 wds:Q73892792-16F005F0-F2DA-4B31-B246-10BB798254E8 wds:Q73892792-3303BB25-3FFF-447C-BBDF-4931664255F4 wds:Q73892792-2392C583-D8E9-44BC-AF9E-CC4CCF6E7753 wds:Q73892792-E19F1AA6-52B4-4920-B409-F4F86BA49330
wdt:P2093
R Volpe S Cirillo A Di Sarno F Scavuzzo R Pivonello G Lombardi M L Landi F Di Salle
rdfs:label
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
skos:prefLabel
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
schema:name
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
p:P50
wds:Q73892792-4BF289FE-AB48-45B0-8908-64D4B91DEA25 wds:Q73892792-85B751BA-8321-4CAB-8D09-A22EF6DB6933 wds:Q73892792-FD9CDCDD-390E-4A7D-BCCB-5D7FFD16639F
wdt:P50
wd:Q64495559 wd:Q21542131 wd:Q56940571
p:P1476
wds:Q73892792-ED3CF6FB-78AF-4C07-BC81-AF8FBB334054
wdt:P1476
Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients
p:P304
wds:Q73892792-BAAE77C9-3713-4280-885C-46F80AE08394
wdt:P304
2247-2252
p:P31
wds:Q73892792-1384685A-8B01-48AD-A767-C8AD459C89F9
wdt:P31
wd:Q13442814
p:P698
wds:Q73892792-F4CB88BE-6C4C-4839-A727-37E4CF3E7955
wdtn:P698
n12:10852458
wdt:P698
10852458
p:P1433
wds:Q73892792-4C9D8F5F-4219-487B-BF57-95898DD4583C
wdt:P1433
wd:Q3186902
p:P433
wds:Q73892792-229909C7-8A39-4A62-B179-4CD32F1A291D
p:P478
wds:Q73892792-280194FE-C906-4C92-9D3D-A468B0791663
wdt:P433
6
wdt:P478
85
p:P356
wds:Q73892792-E06B952A-C9DA-48A6-ABB7-B364B65804D1
wdtn:P356
n8:JCEM.85.6.6657
wdt:P356
10.1210/JCEM.85.6.6657